 |
|
|
| |
The Pharmacokinetics of GS-5816, a Pangenotypic HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment
|
| |
| |
Reported by Jules Levin
EASL 2015 April Vienna
Erik Mogalian,1 Anita Mathias,1 Diana Brainard,1 Gong Shen,1 John McNally,1 Karim Sajwani,1 Richard A. Robson,2 Daniel K. Ries,3 Kenneth Lasseter,4 Thomas Marbury5
1Gilead Sciences, Inc., Foster City, California, USA; 2Christchurch Clinical Studies Trust, Ltd., Christchurch, New Zealand; 3Prism Research, St. Paul, Minnesota, USA; 4Clinical Pharmacology of Miami, Inc., Miami, Florida, USA; 5Orlando Clinical Research Center, Orlando, Florida, USA
|
| |
|
|
|
|
|
